SEARCH

SEARCH BY CITATION

References

  • 1
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995; 333: 15817.
  • 2
    Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 76874.
  • 3
    Multicentre Acute Stroke Trial – Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995; 346: 150914.
  • 4
    The Multicentre Acute Stroke Trial – Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N. Engl. J. Med. 1996; 335: 14550.
  • 5
    Donnan G, Davis SM, Chambers BR et al. for the Australian Streptokinase Trial Investigators. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996; 276: 9616.
  • 6
    Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998; 352: 124551.
  • 7
    Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3–5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999; 282: 201926.
  • 8
    Marler JR, Tilley BC, Lu M et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000; 55: 164955.
  • 9
    Ingall TJ, O'Fallon WM, Asplund K et al. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial. Stroke 2004; 35: 241824.
  • 10
    Lindley RI, Wardlaw JM, Sandercock PA. Alteplase and ischaemic stroke: have new reviews of old data helped? Lancet Neurol. 2005; 4: 24953.
  • 11
    Hoffman JR, Cooper RC. Stroke thrombolysis: we need new data, not more reviews. Lancet Neurol. 2005; 4: 2045.
  • 12
    Hoffman JR. Should physicians give tPA to patients with acute ischemic stroke? And just what is the emperor of stroke wearing? West J. Med. 2000; 173: 14950.
  • 13
    Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283: 11518.
  • 14
    Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch. Intern. Med. 2002; 162: 19942001.
  • 15
    Libman RB, Wirkowski E, Alvir J, Rao TH. Conditions that mimic stroke in the emergency department. Implications for acute stroke trials. Arch. Neurol. 1995; 52: 111922.
  • 16
    Donnan GA, Davis SM, Levi CR. Strategies to improve outcomes after acute stroke. Med. J. Aust. 2003; 178: 30910.
  • 17
    Hoffman JR. Tissue plasminogen activator (tPA) for acute ischaemic stroke: Why has so much been made of so little. Med. J. Aust. 2003; 179: 3334.
  • 18
    Lenzer J. Alteplase for stroke: money and optimistic claims buttress the ‘brain attack’ campaign. BMJ 2002; 324: 7239.
  • 19
    Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287: 61217.
  • 20
    Schwamm LH, Pancioli A, Acker JE 3rd et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Circulation 2005; 111: 107891.